Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...
A new proteomic analysis is shedding a fresh light on the cytokine networks fueling idiopathic pulmonary fibrosis (IPF), ...
Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by progressive scarring of the lungs, leading to respiratory failure and death. Therapies to treat IPF are limited, making ...
A newly reported case study has documented a novel nonsense variant in the RTEL1 gene in a patient with familial pulmonary fibrosis (PF), adding to an expanding understanding of how telomere-related ...
Cell-cell interactions via proteins and ligand-receptor interactions contribute to PF pathogenesis. Single-cell RNA genome sequencing technique and bio-informatics oriented approaches combined with ...
Public Health Relevance Statement: Idiopathic Pulmonary Fibrosis (IPF) is fatal lung disorder for which no U.S. FDA-approved drugs currently exist. This project will lead to the development of novel ...
Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...
The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...
A research team led by the University of Zurich (UZH) has developed a vaccination-based immunotherapy to target fibroblasts of the cells in the lung and liver in mice. Their findings may lead to a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback